Compare Crispr Therapeutics AG (CRSP) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Prudential PLC — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Prudential PLC trades at $28.65 (market cap $35.11B). The key difference: Prudential PLC is far larger — about 7.1× Crispr Therapeutics AG's market cap, and Prudential PLC pays a 1.86% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PUK | |
|---|---|---|
Market Cap | $4.97B | $35.11B |
Sector | Health | Financials |
52-Week High | $76.78 | $33.61 |
52-Week Low | $44.34 | $24.65 |
Enterprise Value | $3.32B | $36.55B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Prudential (PUK) trades at $28.40, up 0.96% with bullish technical signals from moving averages. The stock shows strong fundamentals with a P/E of 9.25, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q2 and Q4 2025, while analyst consensus leans bullish with 50% buy ratings. Positive news includes JP Morgan's catalyst watch ahead of August results and strategic expansion in India.
Outlook remains positive with improving cash flow trends and debt reduction. Key opportunities include Asia growth exposure and strong profitability metrics. Risks include China regulatory uncertainty and Japan sales suspension impacts. The stock presents value with attractive valuation multiples and analyst support for upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
